User profiles for "author:Andreas Lutterotti"

Andreas Lutterotti

University of Zürich
Verified email at usz.ch
Cited by 2997

Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis

ZM Manjaly, NA Harrison, HD Critchley… - Journal of Neurology …, 2019 - jnnp.bmj.com
Fatigue is one of the most common symptoms in multiple sclerosis (MS), with a major impact
on patients' quality of life. Currently, treatment proceeds by trial and error with limited …

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

H Wiendl, R Gold, T Berger, T Derfuss… - Therapeutic …, 2021 - journals.sagepub.com
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous
system characterized by inflammatory demyelination and axonal/neuronal damage. The …

[HTML][HTML] Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders

S Mader, V Gredler, K Schanda, K Rostasy… - Journal of …, 2011 - Springer
Background Serum autoantibodies against the water channel aquaporin-4 (AQP4) are
important diagnostic biomarkers and pathogenic factors for neuromyelitis optica (NMO) …

Antigen-specific tolerance by autologous myelin peptide–coupled cells: a phase 1 trial in multiple sclerosis

A Lutterotti, S Yousef, A Sputtek, KH Stürner… - Science translational …, 2013 - science.org
Multiple sclerosis (MS) is a devastating inflammatory disease of the brain and spinal cord
that is thought to result from an autoimmune attack directed against antigens in the central …

[PDF][PDF] Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis

I Jelcic, F Al Nimer, J Wang, V Lentsch, R Planas… - Cell, 2018 - cell.com
Multiple sclerosis is an autoimmune disease that is caused by the interplay of genetic,
particularly the HLA-DR15 haplotype, and environmental risk factors. How these etiologic …

Getting specific: monoclonal antibodies in multiple sclerosis

A Lutterotti, R Martin - The Lancet Neurology, 2008 - thelancet.com
For more than a decade the only therapies that were available for multiple sclerosis (MS)
were two immunomodulatory drugs—interferon beta and glatiramer acetate—and the …

EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-γ and IL-2

JD Lünemann, I Jelčić, S Roberts… - The Journal of …, 2008 - rupress.org
Symptomatic primary Epstein-Barr virus (EBV) infection and elevated humoral immune
responses to EBV are associated with an increased risk of developing multiple sclerosis …

Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients

DH Whittam, A Cobo-Calvo… - Multiple sclerosis and …, 2020 - Elsevier
Objective To assess the effect of anti-CD20 B-cell depletion with rituximab (RTX) on relapse
rates in myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) …

[HTML][HTML] Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica

S Mader, A Lutterotti, F Di Pauli, B Kuenz, K Schanda… - PloS one, 2010 - journals.plos.org
Background Neuromyelitis optica (NMO), a severe demyelinating disease, represents itself
with optic neuritis and longitudinally extensive transverse myelitis. Serum NMO-IgG …

[PDF][PDF] HLA-DR15 molecules jointly shape an autoreactive T cell repertoire in multiple sclerosis

J Wang, I Jelcic, L Mühlenbruch, V Haunerdinger… - Cell, 2020 - cell.com
The HLA-DR15 haplotype is the strongest genetic risk factor for multiple sclerosis (MS), but
our understanding of how it contributes to MS is limited. Because autoreactive CD4+ T cells …